Uğur Şahin, BioNTech CEO (AP Images)
February 22, 2022 07:13 AM ESTUpdated 03:43 PM
Deals

BioN­Tech signs im­munother­a­py deal with Medi­gene as post-Covid strat­e­gy takes shape

Max Gelman

Senior Editor

Con­tin­u­ing to chart its path for­ward post-pan­dem­ic, BioN­Tech struck a new deal Mon­day aimed at boost­ing its pres­ence in on­col­o­gy.

The Covid-19 vac­cine mak­er signed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times